Matthew McCourt

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Suzanne I.S. Mosely, John E. Prime, Richard C.A. Sainson et al. · Cancer Immunology Research · 2016 · 407 citations

Immunology, Immunoediting, Immunotherapeutic Drug Discovery +21

Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

Ross Stewart, Michelle Morrow, Scott A. Hammond et al. · Cancer Immunology Research · 2015 · 398 citations

Immunology, Immunoediting, Immunologic Mechanism +20

Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein- 1 alpha

B. I. Lord, LB Woolford, L M Wood et al. · Blood · 1995 · 123 citations

Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect

Ling Yu, Wayne A. Border, Ian Anderson et al. · Kidney International · 2004 · 91 citations

Inflammation, Molecular Pharmacology, Hypertension +9

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

Dorothee Greven, E. Suzanne Cohen, Daniëlle M. Gerlag et al. · Annals of the Rheumatic Diseases · 2014 · 71 citations · Full text